Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveil...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_7f73ac6e11cb4f1ebdca8d4fed02fadf | ||
042 | |a dc | ||
100 | 1 | 0 | |a Jing Nie |e author |
700 | 1 | 0 | |a Huina Wu |e author |
700 | 1 | 0 | |a Lei Sun |e author |
700 | 1 | 0 | |a Yanjiao Ding |e author |
700 | 1 | 0 | |a Yepeng Luan |e author |
700 | 1 | 0 | |a Jiyong Wu |e author |
245 | 0 | 0 | |a Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China |
260 | |b Frontiers Media S.A., |c 2023-01-01T00:00:00Z. | ||
500 | |a 1663-9812 | ||
500 | |a 10.3389/fphar.2022.987337 | ||
520 | |a Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective. | ||
546 | |a EN | ||
690 | |a fuzuloparib | ||
690 | |a niraparib | ||
690 | |a olaparib | ||
690 | |a cost-effectiveness | ||
690 | |a maintenance treatment | ||
690 | |a ovarian cancer | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2023) | |
787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.987337/full | |
787 | 0 | |n https://doaj.org/toc/1663-9812 | |
856 | 4 | 1 | |u https://doaj.org/article/7f73ac6e11cb4f1ebdca8d4fed02fadf |z Connect to this object online. |